Maypharm Introduces its whole Lineups with Newly Launched products including METOO, HAIRNA, and SEDY FILL
SEOUL, South Korea and NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Maypharm Co., Ltd. introduces its whole lineups with newly launched products including METOO, HAIRNA, and SEDY FILL. Maypharm is a global company founded in 2015, specializing in cosmetic medicine and dermocosmetic products for skin care and rejuvenation.
Maypharm is committed to providing innovative cosmetic solutions with the highest standards for safety and efficacy, exceeding both patient and provider expectations.
Maypharm has become one of the leading players in the Korean dermocosmetics market, with a global network of distributors for its exclusive brands.
Maypharm offers specialty medical supplies and medical-grade skin care products, including dermal fillers, botulinum toxin, mesotherapy products, cosmetics, and more. Maypharm's mission is to exceed client expectations with the highest standards of quality and service.
All the products are manufactured in South Korea according to Korean Food and Drug Administration (KFDA) regulations.
At Maypharm, it strives to offer the most innovative products with the best quality, cost, and service.
Maypharm is constantly expanding its portfolio, currently working with its own exclusive brands.
1. PHARMACEUTICALS
A. Botulinum Toxin [Medicinal]
2. MEDICAL DEVICES (Dermal & Body Fillers)
A. Hyaluronic Acid
B. Polylactic Acid
C. Collagen
3. SKIN BOOSTERS
A. Premium Skin Booster Line
B. Exosome Complex (Face)
C. High-Concentration HA
D. PN (Polynucleotide)
E. PDRN (Polydeoxyribonucleotide)
4. HAIR CARE
A. Home Care Line
B. Exosome Complex (Scalp)
5. OTHER
A. Cosmetics
B. Lipolysis Solution
C. Derma Device
D. Scalp Device
E. Topical Anesthetic Cream
For further details, please contact us at [email protected], or visit its website at https://www.may-pharm.com/.
Photo - https://mma.prnewswire.com/media/2195300/Maypharm_intro.jpg
Photo - https://mma.prnewswire.com/media/2195301/Maypharm_intro2.jpg
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN94083&Transmission_Id=202308300500PR_NEWS_EURO_ND__EN94083&DateId=20230830)
Поделиться этой статьей